A phase 1, randomized, pharmacokinetic trial of the effect of different meal compositions, whole milk, and alcohol on cannabidiol exposure and safety in healthy subjects-Reference-Cited by-同舟云学术

A phase 1, randomized, pharmacokinetic trial of the effect of different meal compositions, whole milk, and alcohol on cannabidiol exposure and safety in healthy subjects

Published:2020-02 Issue:2 Volume:61 Page:267-277
ISSN:0013-9580
Container-title:Epilepsia
language:en
Short-container-title:Epilepsia

Author:

Crockett Julie¹,Critchley David¹,Tayo Bola¹,Berwaerts Joris¹,Morrison Gilmour¹

Affiliation:

1. GW Research Ltd Cambridge UK

Funder

GW Research Ltd

Publisher

Wiley

Subject

Clinical Neurology,Neurology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/epi.16419

Reference24 articles.

1. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome

2. Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome

3. Effect of Cannabidiol on Drop Seizures in the Lennox–Gastaut Syndrome

4. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial

5. EPIDIOLEX® USPI.Highlights of prescribing information: EPIDIOLEX® (cannabidiol) oral solution. Available at:https://www.epidiolex.com/sites/default/files/EPIDIOLEX_Full_Prescribing_Information.pdf. Accessed May 1 2019.

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Oral formulations for highly lipophilic drugs: Impact of surface decoration on the efficacy of self-emulsifying drug delivery systems;Journal of Colloid and Interface Science;2025-01

2. Exploring the safety of cannabidiol (CBD): A comprehensive in vitro evaluation of the genotoxic and mutagenic potential of a CBD isolate and extract from Cannabis sativa L;Biomedicine & Pharmacotherapy;2024-08

3. Consensus panel recommendations for the optimization of EPIDIOLEX® treatment for seizures associated with Lennox–Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex;Epilepsia Open;2024-07-15

4. Infant formula as a solid lipid dose form for enhancement of the oral bioavailability of cannabidiol for paediatric patients;International Journal of Pharmaceutics;2024-07

5. Quantitative summary on the human pharmacokinetic properties of cannabidiol to accelerate scientific clinical application of cannabis;Naunyn-Schmiedeberg's Archives of Pharmacology;2024-06-08